Compare BX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BX | SNY |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.4B | 116.8B |
| IPO Year | 2007 | N/A |
| Metric | BX | SNY |
|---|---|---|
| Price | $106.30 | $43.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $169.50 | $61.50 |
| AVG Volume (30 Days) | ★ 8.7M | 4.2M |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.44% | 3.66% |
| EPS Growth | ★ 6.91 | N/A |
| EPS | ★ 3.87 | N/A |
| Revenue | ★ $14,450,265,000.00 | N/A |
| Revenue This Year | $14.94 | $3.01 |
| Revenue Next Year | $21.75 | $5.80 |
| P/E Ratio | $26.32 | ★ $6.14 |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $101.81 | $43.51 |
| 52 Week High | $190.09 | $59.17 |
| Indicator | BX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 33.15 | 31.35 |
| Support Level | $105.09 | N/A |
| Resistance Level | $165.14 | $48.97 |
| Average True Range (ATR) | 4.63 | 0.69 |
| MACD | -0.13 | -0.35 |
| Stochastic Oscillator | 25.29 | 2.66 |
Blackstone is the world's largest alternative-asset manager with $1.242 trillion in total asset under management, including $906.2 billion in fee-earning assets under management, at the end of September 2025. The company operates with scale in each of its major product lines: private equity (26% of fee-earning AUM and 33% of base management fees), real estate/real assets (31% and 35%), private credit (34% and 25%), and other alternatives (9% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.